The Alu repetitive elements, which constitute 10% of human genome, may serve as bridges for genomic recombination. However, their roles in tumorigenesis remain to be elucidated. Caspase-activated DNase (CAD), whose gene (hCAD) is mapped at chromosome 1p36, a region frequently displaying hemizygote deletion in many human cancers, is the key enzyme for nucleosome fragmentation during apoptosis. Recently, we detected many aberrant mRNAs for hCAD in many human hepatoma cells. To elucidate the genetic basis leading to the mRNA aberration, we used PCR-based chromosome walking to clone the corresponding genomic DNA identifying a novel Alu/Alu homologous recombination/ deletion within hCAD in HepG2 and Hep3B cells. We then detected similar recombination events in 13 out of the 20 hepatoma tissues and in eight of the para-cancerous cirrhotic livers. The recombination was inclined to occur in males (P ¼ 0.031) and had marginal association with high-grade hepatoma (P ¼ 0.070) and tumor recurrence (P ¼ 0.070). The recombination caused exon-3 deletion, which in turn led to exon-3 skipping or replacement with a partial Alu-sequence, and consequential C-truncation of CAD. Our findings of high frequency of Alu-mediated hCAD deletion in human hepatoma not only underscore the implication of hCAD in hepatocarcinogenesis, but also highlight the potential roles of human repetitive sequences in mediating genome instability in human cancers. Keywords: DNA fragmentation factor B; CAPN; caspase-activated Dnase; CAD; Alu repetitive elements; hepatoma Hepatocellular carcinoma (HCC) is one of the most common human cancers. Molecular genetic studies have revealed frequent loss of heterozygosity within the human chromosome 1p36 region in many cancers, particularly in HCC, suggestive of existence of tumor suppressor genes in this subchromosomal locus (Simon et al., 1991; Cheng et al., 1995; Kuroki et al., 1995; Kaghad et al., 1997; Nagai et al., 1997) . Indeed, two previous independent studies showed that transfer of a normal chromosome 1p region including 1p36 band into a neuroblastoma cell line and a colorectal carcinoma cell line reversed their malignant phenotype (Bader et al., 1991; Tanaka et al., 1993) . However, the putative tumor suppressor genes located in this subchromosomal locus remain to be identified yet.
Caspase-activated DNase (CAD, also DFF40, DFFB, or CPAN) is the key enzyme for chromosomal condensation and nucleosomal fragmentation during cell apoptosis (Liu et al., 1997 Enari et al., 1998; Halenbeck et al., 1998; ; Mukae et al., 1998) . Since apoptosis evasion is one of the essential features of tumor cell transformation, inactivation of CAD has the potential for tumor development Zhang et al., 1998; Hanahan and Weinberg, 2000; Nagata et al., 2003) . Recently, human CAD gene (hCAD) was mapped at chromosome 1p36 (Mukae et al., 1998) . It is, therefore, tempting to speculate that loss of the function of hCAD may be implicated in the carcinogenesis of hepatoma, as well as other human cancers.
Alu-mediated homologous recombination/deletion within the hCADgene We have recently identified many mis-sense mutations and many aberrant hCAD mRNAs in several human HCC cell lines. Most strikingly, skipping or replacement of the exon 3 of the hCAD mRNAs was frequently detected in hepatoma cells (Hsieh et al., 2003) . To elucidate the genetic basis for the frequent exon 3 skipping or replacement in hCAD mRNAs in human hepatoma cells, we used a PCR-mediated chromosome walking method to clone the genomic DNA spanning exons 2-4 within hCAD in a normal liver tissue, and in Hep3B and HepG2 cells. The resulted genomic DNA fragments were with about 10, 3.7, and 3.4 kb in length, suggesting a 6.3 and 6.6 kb internal deletion within hCAD in Hep3B and HepG2 cells, respectively (data not shown). Sequence alignment disclosed two similar events of Alu/Alu (within intron 2 and intron 3, respectively) homologous recombination leading to a 6.3 (between Alu b and Alu i) ( Figure 1a ) and a 6.6 kb (between Alu a and Alu i) (Figure 1b) internal deletion containing the exon 3 of hCAD in Hep3B and HepG2 cells, respectively (Figure 1c ).
High-frequency Alu-mediated recombination/deletion within hCAD in human hepatoma
We designed PCR assays to examine whether similar Alu/Alu homologous recombination/deletion occurred in human HCC tissues and the corresponding allelotypes ( Figure 1c) . Fidelity of the PCR assays was confirmed in the genomic DNA derived from Hep3B and HepG2 cells as positive controls, and from a normal liver and three peripheral blood lymphocyte samples of healthy individuals as negative controls (Figure 2a ). We then used them to assay the allelotypes of hCAD in 20 HCC samples and found 13 positive for the Alumediated deletion ( Figure 2b ; Table 1 ). The PCR results were confirmed by sequencing analysis (data not shown). In addition, eight out of 13 HCC samples positive for the Alu-mediated hCAD deletion were also positive for the deletion in their counterparts of para-HCC liver tissues (data not shown). The deletion was primarily occurred in only one allele with the other intact in all the hepatoma cells and tissues (data not shown). We also correlated Alu-mediated hCAD deletion to the underlying liver disease and clinical manifestations (Table 1) . We found that Alu-mediated hCAD deletion was independent of patients' age (P ¼ 0.156), underlying cause of hepatitis (P ¼ 0.106), presence of cirrhosis (P ¼ 0.730), preoperative serum alpha-fetoprotein level (P ¼ 1.000), or tumor size (P ¼ 0.502). However, it was inclined to occur in male patients (P ¼ 0.031), and was marginally associated with high histological grade (P ¼ 0.070) and tumor recurrence within three years after initial hepatectomy (P ¼ 0.070) ( Table 1) . On the other hand, all the para-hepatoma liver tissues positive for the deletion were positive for the deletion in their counterpart of HCC tissues and were in the cirrhotic stage. Since para-hepatoma cirrhotic livers usually present monoclonal originality, they have been believed to be precancerous liver tissues (Yeh et al., 2001) . Therefore, the Alu-mediated hCAD deletions reported herein were somatic mutations rather than germ-line events and they could occur in the early stage of hepatocarcinogenesis.
The Alu-mediated hCAD deletion led to C-truncated CAD Theoretically, the Alu-mediated exon-3 deletion within hCAD resulted in either exon-3 skipping or replacement with a partial sequence of Alu-element, frameshift and premature termination of the reading frame and consequential C-truncation of the CAD products. To detect the C-truncated CAD in hepatoma cells and HCC tissues, we used a polyclonal antibody raised against the N-terminal 19 amino acids of CAD to conduct immunoblotting analysis. We found that besides the 40 kDa full-sized CAD there were C-truncated CADs with molecular weight around 20 kDa in Hep3B, HepG2 cells and the HCC tissue samples positive for the Alumediated exon 3 deletions (Figure 3) . By contrast, only the full-sized CAD was detected in the HCC tissues negative for the deletion (Figure 3b) .
Of note, the C-truncated CAD preserved the N-side domain, which was responsible for interaction with its inhibitor, ICAD (inhibitor of CAD). Since ICAD functions not only as an inhibitor for CAD but also a chaperon for CAD correctly folding during its synthesis Genomic DNA was extracted as described before . The three PCR assays to detect the Alu-mediated deletion and to determine the allele-type for the hCAD gene ( Figure 1c ). Genomic fragment spanning the exon 2-4 was first amplified with the outer primer pair (5 0 -TCCTCCTCCTGTTGCTTCTC-3 0 and 5 0 -AGCA TACCCGGTCTTCACTC-3 0 ). Amplification was performed using 30 cycles of 951C for 30 s and 651C for 6 min. Subsequently, PCR with primer pair CAD #1/CAD #2 (CAD #1: 5 0 -GCGCTTT ATCCTCCTCTCTTCGCTG-3 0 ; CAD#2: 5 0 -ACACGCAGTG GAGTGAATGGACAGA-3 0 ) was used to detect Alu-mediated recombination/deletion encompassing the exon 3, and the expected size of the deleted fragments was around 3-5 kb (vs 10 kb for the nondeleted sequences, which was undetectable in this assay). The PCR products were directly cloned and subjected for sequencing analysis using the methods as reported previously (Hsieh et al., 1997) . To determine the intact alleles other than that with deletion, we used primer pair CAD #1/CAD #3 (CAD #3: 5 0 -GTGCAACTTCCTGGGAATCTGTCA-3 0 ) and CAD #4/CAD #2 (CAD #4: 5 0 -GGTCATCGGCATTAGGTACATGCACA-3 0 ) for second-round PCR to detect the genomic fragments containing the 5 0 -and 3 0 -recombination ends within hCAD, respectively. The expected sizes would be 555 and 690 bp, respectively. (a) The PCR results derived from two hepatoma cell lines (HepG2 and Hep3B; lanes 1 and 2, respectively), a normal liver (lane 3), three peripheral blood lymphocyte samples from three healthy individuals (lanes 4-6), and a flank control (À). (b) The representative PCR results for the detection of the Alu-mediated hCAD deletions in human hepatoma tissues. Lane 6 is the negative control for PCR (Halenbeck et al., 1998; Zhang et al., 1998; Nagase et al., 2003) , the C-truncated CAD may sequestrate ICAD from interaction with the wild-type CAD, so as to interfere with the activity of the wild-type CAD. Functional assays to examine the biological significance of the C-truncated CAD are currently ongoing.
Alu-mediated genome recombination in human diseases
The Alu elements, approximately 300 bp in length, construct about 10% of the whole human genome and are estimated to have about a million copies for each haploid genome (Mighell et al., 1997; Batzer and Deininger, 2002) . They are dispersed throughout the human genome and occur on the average once every 3-4 kb (Smit, 1999; Rowold and Herrera, 2000) . The average inter-Alu homology is about 70-98% (Schmid, 1996; Rowold and Herrera, 2000) . The dispersed distribution and high homology amongst the Alu elements provide abundant opportunities for homologous recombination (Schmid, 1996; Kolomietz et al., 2001; Stenger et al., 2001) . So far, most Alu-mediated genomic recombinations were primarily found in human germ lines, which usually presented as inherited disorders, such as familiar hypercholesterolemia, alphathalassemia, angioneurotic edema, Ehlers-Danlos syndrome, Glanzmann thromboasthenia and C3 deficiency (Schmid, 1996; Deininger and Batzer, 1999) . They have also been found in some familial cancers, such as breast cancer, and hereditary nonpolyposis colorectal cancer, but are relatively fewer in sporadic cancers (Deininger and Batzer, 1999) . Herein, we report for the first time the repeated occurrence of Alu-mediated genomic mutations in a noninherited human cancer, hepatoma. We speculate that similar implication of human genome repetitive sequences in genomic mutation should be present in other potential tumor-related genes in other human cancers.
Hypothetic recombinogenic sequences at the recombination breakpoint sites It has been reported that Alu/Alu recombination was highly biased towards specific genes (Lehrman et al., 1987; Chen et al., 1989; Stoppa-Lyonnet et al., 1990; Jeffs et al., 1998; Deininger and Batzer, 1999) , which tended to have a relatively large number of Alu sequences (Stoppa-Lyonnet et al., 1990; Deininger and Batzer, 1999) . For example, the unusually high proportion of the Alu elements in the BRCA1 gene was thought to contribute to the frequent occurrence of genomic rearrangement mutations in familial breast and ovarian cancers (Rohlfs et al., 2000) . In hCAD, there are 24 copies of the Alu elements representing about 25% of the whole hCAD sequences, much higher than that of the 10% of the whole human genome sequences (Lander et al., 2001; Venter et al., 2001) . It was also suggested that the Alu elements separated by a short (o20 bp) and inverted orientation are potential nuclei of genomic instability (Lobachev et al., 2000; Stenger et al., 2001) . Certainly, most of such closely spaced, highly homologous inverted Alu elements have been excluded from human genome and are indeed rarely present in the human genome (Lobachev et al., 2000; Rowold and Herrera, 2000) . On the other hand, the recombination appears to take place in a preferred location within the Alu elements (Rudiger et al., 1995; Batzer and Deininger, 2002) . A consensus 26 bp core sequences, which have been generally found at or close to the sites of recombination, are thought to be recombinogenic (Rudiger et al., 1995) . Moreover, a pentanucleotide motif 'CCGAC' homologous to a recombinogenic motif, chi, in Escherichia coli, is commonly present within the 26 bp core sequences. Indeed, the consensus 26 bp core sequences and the chi pentanucleotide are also present at or close to the sites of hCAD recombination in Hep3B and HepG2 cells (Figure 1a and b), and hepatoma tissues. Studies to address the mechanism that triggers homologous recombination between genomic repetitive sequences particularly in hepatoma cells are currently ongoing.
In summary, we report that a novel Alu-mediated genomic recombination/deletion within hCAD repeatedly occurred in human HCC. It occurred as a somatic mutation and might take place in the early stage of hepatocarcinogenesis. It led to C-truncation of CAD. Our findings not only highlight the implication of hCAD in hepatocarcinogenesis, but also underscore the significance of Alu-repetitive elements in mediating genomic mutations in human hepatoma. Figure 3 Immunoblotting analysis to detect CAD in hepatoma cells and tissues. Cells or tissue samples were homogenized and lysed in a buffer containing 50 mM Tris-HCl pH 8.0, 120 mM NaCl, 0.5% NP-40, 0.25% Na deoxycholate, 1 mM DTT, 2 mg/ml aprotinin, and 2 mg/ml leupeptin. About 50 mg of the lysate proteins were then subjected to electrophoresis followed by immunoblotting analysis using antibodies raised against N-19 amino-acid peptide (CAPN N-19, Santa Crutz). 
